Following the news of the $3 billion settlement between the government and GlaxoSmithKline for illegal promotion of prescription drugs for unapproved uses, Mr. Goozner say many assume off-label promotion will become a thing of the past. However, he wrote, just because companies are more focused on compliance with the law doesn’t mean they aren’t still promoting the drugs.
Related Articles on Pharmaceuticals:
AMA Adopts New Policy for Drug Shortages
Senate Proposal Would Allow FDA to Fast Track Drugs for Unmet Needs
10 Recent FDA Drug and Medical Device Decisions
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.